Avalon GloboCare (ALBT) Stock Price, News & Analysis

Company Overview

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies. Its technology platforms include exoSTAMP, designed for highly sensitive isolation and analysis of circulating exosomes, and exoSC, aimed at scalable manufacturing of exosome-based products.

The company maintains strategic collaborations with academic and clinical partners to accelerate development timelines and broaden the potential application of its technologies. These partnerships support Avalon’s efforts to optimize manufacturing processes, refine product specifications and initiate clinical trials in oncology and, potentially, viral diseases where cell therapy approaches can address unmet medical needs.

Founded in 2016 and publicly listed on NASDAQ under the ticker ALBT, Avalon GloboCare is led by Dr. Leem Chao, its Chairman and Chief Executive Officer. Under his leadership, the company has expanded its footprint across key biopharma hubs and continues to advance a diversified portfolio of innovative therapies and diagnostics designed to improve patient outcomes worldwide.

Key Stats

• Today's Range: $2.40 to $2.60
• 50-Day Range: $1.94 to $2.97
• 52-Week Range: $1.87 to $11.66
• Volume: 104,052 shs
• Average Volume: 62,230 shs
• Market Capitalization: $9.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Avalon GloboCare Stock Analysis - MarketRank™

Avalon GloboCare scored higher than 32% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Avalon GloboCare.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Avalon GloboCare is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Avalon GloboCare is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.81% of the float of Avalon GloboCare has been sold short.

Short Interest Ratio / Days to Cover

Avalon GloboCare has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Avalon GloboCare has recently decreased by 75.55%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Avalon GloboCare does not currently pay a dividend.

Dividend Growth

Avalon GloboCare does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -1.06

Percentage of Shares Shorted

6.81% of the float of Avalon GloboCare has been sold short.

Short Interest Ratio / Days to Cover

Avalon GloboCare has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Avalon GloboCare has recently decreased by 75.55%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.49

News Sentiment

Avalon GloboCare has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Avalon GloboCare this week, compared to 1 article on an average week.

MarketBeat Follows

12 people have added Avalon GloboCare to their MarketBeat watchlist in the last 30 days. This is an increase of 140% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Avalon GloboCare insiders have not sold or bought any company stock.

Percentage Held by Insiders

37.30% of the stock of Avalon GloboCare is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 1.42% of the stock of Avalon GloboCare is held by institutions.

ALBT Stock Analysis - Frequently Asked Questions

How have ALBT shares performed this year?

Avalon GloboCare's stock was trading at $3.26 at the beginning of 2025. Since then, ALBT stock has decreased by 23.3% and is now trading at $2.50.

How were Avalon GloboCare's earnings last quarter?

Avalon GloboCare Corp. (NASDAQ:ALBT) released its earnings results on Thursday, August, 14th. The company reported ($2.02) earnings per share for the quarter. The business earned $0.35 million during the quarter.

When did Avalon GloboCare's stock split?

Shares of Avalon GloboCare reverse split on Monday, October 28th 2024.The 1-15 reverse split was announced on Thursday, October 24th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Avalon GloboCare?

Shares of ALBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Avalon GloboCare own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Avalon GloboCare investors own include Sangamo Therapeutics (SGMO), Ford Motor (F), Pfizer (PFE), Plug Power (PLUG), NVIDIA (NVDA), Intel (INTC).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/10/2025
• Next Earnings (Estimated): 11/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ALBT
• Previous Symbol: NASDAQ:AVCO
• CIK: 1630212
• Web: www.avalon-globocare.com
• Phone: (732) 780-4400
• Fax: 732-780-5600
• Employees: 5
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($19.96)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.90 million
• Net Margins: -1,451.94%
• Pretax Margin: -1,463.60%
• Return on Equity: N/A
• Return on Assets: -75.12%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.06
• Quick Ratio: 0.06

Sales & Book Value

• Annual Sales: $1.33 million
• Price / Sales: 7.22
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($11.37) per share
• Price / Book: -0.22

Miscellaneous

• Outstanding Shares: 3,840,000
• Free Float: 2,405,000
• Market Cap: $9.60 million
• Optionable: Not Optionable
• Beta: 0.02